The use of metoclopramide in ileus

A look at duration of therapy

Scott Bolesta, Brian L Erstad

Research output: Contribution to journalArticle

Abstract

Purpose: The authors conducted a retrospective chart review to determine if metoclopramide was being used properly for ileus and if it caused any adverse effects. Methods: All adult patients admitted to the institution's ICUs between November 10, 2000 and January 31, 2001 were evaluated for enrollment. Data was obtained from medication administration records, patient flow sheets, the computer-based laboratory and report systems, and a database of adverse drug events. Bowel movements were used to assess effectiveness. The primary endpoint was the length of time metoclopramide was continued after the first bowel movement. A secondary endpoint was the occurrence of any adverse effects related to metoclopramide administration. Results: There were a total of 32 patients who received metoclopramide for ileus during the time period studied. The average number of days people received metoclopramide was 11.5 ± 7.3 days. The mean time to first bowel movement was 1.7 ± 1.4 days. Patients had therapy continued after first bowel movement for an average of 10.7 ± 7.1 days. Extrapyramidal symptoms possibly occurred in 3% of the patients. Conclusion: The results suggest that metoclopramide was used for the treatment of ileus in ICU patients for prolonged periods of time. This overuse may place patients at risk for adverse events and may also occur at other institutions.

Original languageEnglish (US)
Pages (from-to)949-952
Number of pages4
JournalHospital Pharmacy
Volume37
Issue number9
StatePublished - Sep 2002
Externally publishedYes

Fingerprint

Metoclopramide
Ileus
Intensive care units
Therapeutics
Drug-Related Side Effects and Adverse Reactions
Databases
Pharmaceutical Preparations

Keywords

  • Extrapyramidal symptoms
  • Ileus
  • Metoclopramide

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

The use of metoclopramide in ileus : A look at duration of therapy. / Bolesta, Scott; Erstad, Brian L.

In: Hospital Pharmacy, Vol. 37, No. 9, 09.2002, p. 949-952.

Research output: Contribution to journalArticle

@article{4650bc20144d4353bb6fde37d8bd6527,
title = "The use of metoclopramide in ileus: A look at duration of therapy",
abstract = "Purpose: The authors conducted a retrospective chart review to determine if metoclopramide was being used properly for ileus and if it caused any adverse effects. Methods: All adult patients admitted to the institution's ICUs between November 10, 2000 and January 31, 2001 were evaluated for enrollment. Data was obtained from medication administration records, patient flow sheets, the computer-based laboratory and report systems, and a database of adverse drug events. Bowel movements were used to assess effectiveness. The primary endpoint was the length of time metoclopramide was continued after the first bowel movement. A secondary endpoint was the occurrence of any adverse effects related to metoclopramide administration. Results: There were a total of 32 patients who received metoclopramide for ileus during the time period studied. The average number of days people received metoclopramide was 11.5 ± 7.3 days. The mean time to first bowel movement was 1.7 ± 1.4 days. Patients had therapy continued after first bowel movement for an average of 10.7 ± 7.1 days. Extrapyramidal symptoms possibly occurred in 3{\%} of the patients. Conclusion: The results suggest that metoclopramide was used for the treatment of ileus in ICU patients for prolonged periods of time. This overuse may place patients at risk for adverse events and may also occur at other institutions.",
keywords = "Extrapyramidal symptoms, Ileus, Metoclopramide",
author = "Scott Bolesta and Erstad, {Brian L}",
year = "2002",
month = "9",
language = "English (US)",
volume = "37",
pages = "949--952",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "9",

}

TY - JOUR

T1 - The use of metoclopramide in ileus

T2 - A look at duration of therapy

AU - Bolesta, Scott

AU - Erstad, Brian L

PY - 2002/9

Y1 - 2002/9

N2 - Purpose: The authors conducted a retrospective chart review to determine if metoclopramide was being used properly for ileus and if it caused any adverse effects. Methods: All adult patients admitted to the institution's ICUs between November 10, 2000 and January 31, 2001 were evaluated for enrollment. Data was obtained from medication administration records, patient flow sheets, the computer-based laboratory and report systems, and a database of adverse drug events. Bowel movements were used to assess effectiveness. The primary endpoint was the length of time metoclopramide was continued after the first bowel movement. A secondary endpoint was the occurrence of any adverse effects related to metoclopramide administration. Results: There were a total of 32 patients who received metoclopramide for ileus during the time period studied. The average number of days people received metoclopramide was 11.5 ± 7.3 days. The mean time to first bowel movement was 1.7 ± 1.4 days. Patients had therapy continued after first bowel movement for an average of 10.7 ± 7.1 days. Extrapyramidal symptoms possibly occurred in 3% of the patients. Conclusion: The results suggest that metoclopramide was used for the treatment of ileus in ICU patients for prolonged periods of time. This overuse may place patients at risk for adverse events and may also occur at other institutions.

AB - Purpose: The authors conducted a retrospective chart review to determine if metoclopramide was being used properly for ileus and if it caused any adverse effects. Methods: All adult patients admitted to the institution's ICUs between November 10, 2000 and January 31, 2001 were evaluated for enrollment. Data was obtained from medication administration records, patient flow sheets, the computer-based laboratory and report systems, and a database of adverse drug events. Bowel movements were used to assess effectiveness. The primary endpoint was the length of time metoclopramide was continued after the first bowel movement. A secondary endpoint was the occurrence of any adverse effects related to metoclopramide administration. Results: There were a total of 32 patients who received metoclopramide for ileus during the time period studied. The average number of days people received metoclopramide was 11.5 ± 7.3 days. The mean time to first bowel movement was 1.7 ± 1.4 days. Patients had therapy continued after first bowel movement for an average of 10.7 ± 7.1 days. Extrapyramidal symptoms possibly occurred in 3% of the patients. Conclusion: The results suggest that metoclopramide was used for the treatment of ileus in ICU patients for prolonged periods of time. This overuse may place patients at risk for adverse events and may also occur at other institutions.

KW - Extrapyramidal symptoms

KW - Ileus

KW - Metoclopramide

UR - http://www.scopus.com/inward/record.url?scp=0036718424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036718424&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 949

EP - 952

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 9

ER -